Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
Arthur MatthysBenjamin BardelFabien Le BrasAlain CréangeTarik NordineRomain GounotSaskia Ingen-Housz-OroMuriel CarvalhoJean-Pascal LefaucheurCorinne HaiounViolaine Planté-BordeneuveThierry GendrePublished in: European journal of neurology (2024)
Brentuximab vedotin-induced neuropathy is an overlooked complication. Based on four easily identifiable "red flags", we provide an algorithm to help non-neurologist physicians that care for BV-treated patients to detect BV-IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
Keyphrases
- hodgkin lymphoma
- end stage renal disease
- newly diagnosed
- machine learning
- healthcare
- primary care
- ejection fraction
- deep learning
- chronic kidney disease
- lps induced
- lipopolysaccharide induced
- oxidative stress
- prognostic factors
- peritoneal dialysis
- high glucose
- inflammatory response
- endothelial cells
- pain management
- drug induced
- bone marrow
- chronic pain
- smoking cessation